Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. I rate AGIO stock as Buy. Read my update.